EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials

Mart A F J van de Laar, Rainer Schöfl, Marlou Prevoo, Jan Jastorff iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0284358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Mart A F J van de Laar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Gastrointestinal Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grünenthal GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and rheumatic conditions. To facilitate patient management, we determined the predictive value of gastrointestinal (GI) symptoms and risk factors for the development of NSAID-associated GI injuries.

Methods

Post-hoc analysis of pooled data from naproxen treatment arms of two identical, randomized, double-blind, controlled phase 3 trials in arthritis patients at risk of GI adverse events. Endoscopic incidence of GI ulcers at baseline, and 1, 3, and 6 months was employed as a surrogate parameter for GI injury. For GI symptom analysis, Severity of Dyspepsia Assessment questionnaire was used. For GI risk factor analysis, the high risk factors: previous GI injury, concomitant selective serotonin reuptake inhibitors or corticosteroids, ulcer history, concomitant low-dose aspirin, and age >65 years were employed.

Results

Data of 426 naproxen patients were analyzed. Distribution of GI symptoms between patients with and without ulcer was similar; about one third of patients developing an ulcer reported no GI pain symptoms. GI symptoms experienced under naproxen treatment were thus not indicative of GI injury. The proportion of patients developing an ulcer increased with the number of risk factors present, however, about a quarter of patients without any of the analyzed risk factors still developed an ulcer.

Conclusion

GI symptoms and the number of risk factors are not reliable predictors of NSAID-induced GI injury to decide which patients need gastroprotection and will lead to a large group of patients with GI injuries. A preventive rather than reactive approach should be taken.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalGastrointestinal DiseasesHumansAgedNaproxenUlcerRisk FactorsEndoscopyPainRandomized Controlled Trials as Topic

Substanzen

Anti-Inflammatory Agents, Non-SteroidalNaproxen

Autor:innen und Institutionen

  • Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands.
  • Department of Internal Medicine IV, Ordensklinikum Barmherzige Schwestern, Linz, Austria.
  • Grünenthal GmbH, Aachen, Germany.

ORCID-Profile: Jan Jastorff

Förderung

  • Grünenthal GmbH

Zitieren

APA

van de Laar, M. A. F. J., Schöfl, R., Prevoo, M., & Jastorff, J. (2023). Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0284358

Vancouver

van de Laar MAFJ, Schöfl R, Prevoo M, Jastorff J. Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials. PLOS ONE. 2023. doi:10.1371/journal.pone.0284358

BibTeX
@article{vandeLaar2023,
  author = {van de Laar, Mart A F J and Schöfl, Rainer and Prevoo, Marlou and Jastorff, Jan},
  title = {Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0284358}
}
Kostenlos starten →